The last of the triumvirate is romosozumab, the drug for post-menopausal osteoporosis being co-developed with Amgen ... now sell alongside its own neurology products, plus a number of future ...

Neurocrine Biosciences, Inc.'s potential for growth in the biopharma sector is strong despite recent setbacks, making its ...

AstraZeneca’s AZN third-quarter 2024 core earnings of $1.04 per American depositary share (ADS) beat the Zacks Consensus ...

neurology, and other applications. In 2022, the musculoskeletal disorders segment accounted for the largest market share.

Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The global neuromodulation device market will be worth $11.4bn by 2033, as per a market model from GlobalData.

The news comes just days after BioMarin also announced a major change to its senior leadership team aimed at boosting its pipeline, with former Amgen executive Greg Friberg named as chief R&D ...

Johnson & Johnson shows strong progress in oncology with Darzalex sales and regulatory filings, leading to a 'Buy' rating ...

Neurology is a medical specialty that is concerned with the study of structure, function and disorders of the nervous system. Endocisternal neural interfaces with wireless and magnetoelectrically ...